@biovie.bsky.social
At BioVie we believe that every person deserves to live free from the limitations of aging and disease. bioviepharma.com
November National FAMILY CAREGIVERS Month and National ALZHEIMER'S DISEASE AWARENESS Month Image of a heart with two hands inside attached to a ribbon
This month we honor those living with #Alzheimer’s and the families, clinicians, & researchers supporting them. And THANK YOU to the millions of #caregivers providing essential, heartfelt assistance to loved ones with #neurodegenerative disorders.
#AlzheimersDiseaseAwareness #FamilyCaregiversMonth
LONG COVID UPDATE BioVie Presents at 3rd Long COVID International Conference 2025 November 19-20, 2025 A Phase 2 Trial Designed to Enhance Signal Detection in an Evaluation of Bezisterim (NE3107) for the Treatment of Neurological Symptoms of Long COVID
We’re at #LongCOVIDIntl 2025 presenting our ongoing P2 ADDRESS-LC trial evaluating the efficacy, safety, & tolerability of bezisterim in participants with #LongCOVID enriched for #BrainFog & #fatigue.
Learn about the currently enrolling trial: www.addresslongcovid.com
@academicmededu.bsky.social
REPLAY AVAILABLE Investor Webinar and Q&A Cuong Do President & CEO, BioVie
Earlier this month our CEO held a virtual investor webinar to discuss bezisterim for the treatment of neurological & neurodegenerative diseases.
Catch the replay here: www.youtube.com/watch?v=ts_1...
#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI
PRESENTATION Bezisterim Effects on Aging in Alzheimer's Subjects Chris Reading, PhD Senior Vice President Alzheimer's Disease Program
Dr. Chris Reading, SVP of our Alzheimer’s program, presented at Longevity Biotech 2025 in Boston. He discussed bezisterim’s multifaceted MoA, targeting #inflammation & #insulinresistance in the brain, 2 key drivers of #neurodegenerative disease.
#Longevity #Biotech #Aging #AlzheimersDisease
INVESTOR WEBINAR and Q&A Date: Wednesday, October 8, 2025 Time: 4:15 p.m. EST
A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim for the treatment of neurological & neurodegenerative diseases.
Register here: investors.bioviepharma.com/news/news-de...
#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID
Corporate Update BioVie to Host Live Investor Webinar and Q7A on Wednesday, October 8
Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on October 8.
Register here: investors.bioviepharma.com/news/news-de...
#Neuroinflammation #InsulinResistance
#Alzheimers #Parkinsons #LongCOVID #NeuroSky
On #WorldAlzheimersDay, we recognize the nearly 60M people worldwide living w/ Alzheimer’s & other forms of dementia.
We're committed to advancing the science of #neuroinflammation -a root cause of #Alzheimer’s, #Parkinson’s & other diseases of #aging.
#InsulinResistance #BIVI
For information about the currently enrolling ADDRESS-LC trial in the U.S., visit addresslongcovid.com
19.09.2025 12:57 — 👍 0 🔁 0 💬 0 📌 0
"...there are 17 million Americans who are affected with long COVID. And 3 million have it so badly that they have had to quit or change their jobs simply because they cannot put up with the physical demands And we believe we have a shot at addressing that. So we have received a $13 million grant to conduct a phase 2 exploratory trial where we're enrolling 200 patients to see if we can help address brain fog, malaise, and fatigue." -Cuong Do, President & CEO, BioVie
Our CEO, Cuong Do, recently joined Kevin McCullough to share an update on the clinical trials of bezisterim for patients with #Parkinson’s disease & #LongCOVID.
Listen here: podcasts.apple.com/us/podcast/t...
#Neuroinflammation #InsulinResistance #Aging #ClinicalTrials #Neurology #Neurosky #BIVI
Long Covid Update Press Release headline: BioVie Presents ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
We presented the ADDRESS-LC P2 trial design of our ongoing study exploring bezisterim to treat #neurological symptoms at the #LongCOVID @keystonesymposia.bsky.social.
Learn more: investors.bioviepharma.com/news/news-de...
#BrainFog #Fatigue #Neuroinflammation #KSLongCOVID26
The role of neuroinflammation is no longer considered a peripheral component in the treatment of #Parkinson’s disease. It is central… and offers a new array of therapeutic promise.
@parkinsondotorg.bsky.social @gohealio.bsky.social
#Neuroinflammation #InsulinResistance #Neurology #Neurosky
If you missed @solveme.bsky.social's webinar on the ADDRESS-LC #ClinicalTrial studying the impact of bezisterim on #BrainFog and #Fatigue in #LongCovid, watch the replay here: www.youtube.com/watch?v=-mMg...
#Neuroinflammation #Neurology #Neurosky
BioVie was a poster winner at this year’s #ATMRD2025. Our and lead author spoke with @neurologylive.bsky.social about the presentation.
Watch here: www.neurologylive.com/view/designi...
#ParkinsonsDisease #ClinicalTrials #Neuroinflammation #Neurology #Neurosky
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced and Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
We presented data that suggest bezisterim’s potential to target epigenetic-driven age deceleration as a treatment for #Alzheimers disease and other #neurodegenerative diseases of aging.
Learn more: investors.bioviepharma.com/news/news-de...
#Aging #Longevitiy #Neuroscience #Neurosky #BIVI
We’re thrilled to announce the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to our Board of Directors.
Details: investors.bioviepharma.com/news/news-de...
#Biotech #Neuroinflammation #Neurology #BIVI
A rectangular white graphic with blue shading in corners promotes "The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain Fog and Fatigue in People with Long Covid" which takes place on Tuesday, July 22 at 3 pm PT / 6 pm ET. The ad includes four headshots of panelists. 1. Penny Markham, Senior VP BioVie, a woman with long cark hair and wearing a blue jacket. 2. Michael Peluso, MD, Asst. Professor of Medicine, University of California, San Francisco, a man with short brown hair, mustache and beard, wearing a white and blue checkered shirt 3. Ezra Spier, Creator, LongCovidStudies.net & member of Patient-Led Research Collaborative, a man with brown hair and wearing a yellow and brown plaid shirt 4. Emily Taylor, Solve M.E. President and CEO, a woman with shoulder-length brown hair wearing glasses and a blue shirt. The Solve M.E. logo is placed at the bottom left corner of the graphic.
Register today for our webinar “The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain Fog and Fatigue in People with #LongCovid.”
Sign up here:
us02web.zoom.us/webinar/regi...
ALZHERIMER'S UPDATE: BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
In a keynote session today at #ARC2025, we presented data highlighting bezisterim’s potential to target epigenetic-driven age acceleration as a treatment for #Alzheimers and other #neurodegenerative diseases of aging.
Learn more here: investors.bioviepharma.com/news/news-de...
#Neurosky #BIVI
Poster from ATMRD
See our poster here:
03.07.2025 18:43 — 👍 0 🔁 0 💬 0 📌 0![“And so bezisterim is a drug that targets [insulin receptors] as they become faulty. And it improves their function, which improves cellular metabolism, which we hope would prevent folding of these, misfolding of proteins that would lead to alpha-synuclein accumulation.”
-Mark Stacy, MD
William E. Murray Professor of Neurology, Medical University of South Carolina](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:vasxq5rv5deurlzhfomnxjdp/bafkreicl6ru2c7pxaqug3wv6dvx37z3g7umgxqmypuxdl6w4kqk4n2mw6u@jpeg)
“And so bezisterim is a drug that targets [insulin receptors] as they become faulty. And it improves their function, which improves cellular metabolism, which we hope would prevent folding of these, misfolding of proteins that would lead to alpha-synuclein accumulation.” -Mark Stacy, MD William E. Murray Professor of Neurology, Medical University of South Carolina
Dr. Mark Stacy highlighted the potential of bezisterim as a treatment targeting #neuroinflammation in Parkinson's disease & its innovative P2 trial design on Practical Neurology's podcast.
Listen here: practicalneurology.com/diseases-dia...
#ParkinsonsAwareness #BrainHealthMonth #Neurology #BIVI
"By combining an innovative therapeutic approach with a decentralized model, we are exploring the potential of bezisterim to impact the course of Parkinson's disease and set a precedent for how studies can be more inclusive, ,accessible and patient-focused." -Cuong Do, President & CEO of BioVie
Our hybrid, decentralized trial of bezisterim (NE3107) in early Parkinson’s Disease prioritizes patient access and participation.
Learn more: investors.bioviepharma.com/news/news-de...
#ATMRD #ParkinsonsDisease #MovementDisorders #Neurology #BIVI
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD 2025)
We will be presenting a poster at #ATMRD highlighting the decentralized design of our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease.
Learn more: investors.bioviepharma.com/news/news-de...
#ParkinsonsDisease #MovementDisorders #Neurology #Medsky
A new #LongCovid clinical trial is enrolling for bezisterim, an investigational anti-inflammatory drug that crosses the blood-brain barrier.
It has been studied in neurological & neurodegenerative disorders, including Alzheimer’s & Parkinson’s. 1/
We’re enrolling a new trial for bezisterim to address these symptoms: www.addresslc.com
#BrainAwarenessMonth #NeuroCOVID #neuroskyence
#biotech
Understanding the shared pathologies across long COVID and diseases of aging like Alzheimer's could open doors to shared therapeutic strategies across chronic brain disorders.
#LongCOVID neurological symptoms – brain fog, memory loss, fatigue – mirror those of Alzheimer’s & Parkinson’s. The link? Chronic neuroinflammation. Shared pathways suggest post-viral syndromes may accelerate age-related neurodegeneration.
16.06.2025 13:53 — 👍 5 🔁 1 💬 1 📌 0
June is Alzheimer’s & Brain Health Awareness Month, a time to spotlight not only Alzheimer’s but also the broader challenges facing brain health, including Parkinson’s disease. Learn more at www.sunrisePD.com/
#ParkinsonsAwareness #BrainHealthMonth #neurosci #neuroskyence #Neurology
Last week we held a virtual KOL event with two leading experts in the field to discuss the unmet need in #ParkinsonsDisease along with an overview of our currently enrolling SUNRISE-PD trial in newly diagnosed patients.
Catch the replay here: lifescievents.com/event/biovie...
#BIVI #Neuroscience
Alzheimer’s disease is the 7th leading cause of death globally – yet, despite decades of effort, there are significant gaps in the fight to #ENDALZ.
We’re joining @alzassociation.bsky.social this month in raising awareness. Learn more: www.alz.org/abam/overvie...
#AlzheimersAwareness #BrainHealth
REMINDER: Join us today at 12pm EDT for a virtual event to learn more about the urgent unmet needs and treatment landscape in #ParkinsonsDisease and our ongoing SUNRISE-PD clinical trial in newly diagnosed patients.
Register here: lifescievents.com/event/biovie...
#Medsky #Neurosky #ClinicalTrials
We're leading the charge in targeting #neuroinflammation - a root cause of Alzheimer’s, Parkinson’s & long COVID. Cuong Do, BioVie's CEO, joins The Longevity Formula podcast to discuss BioVie’s novel approach with bezisterim.
Listen: podcasts.apple.com/us/podcast/t...
#Medsky #Aging #Longevity
Enrollment is open for our SUNRISE-PD clinical trial in patients who have been diagnosed with #ParkinsonsDisease disease but have not been prescribed carbidopa/levodopa.
Patients who qualify can participate from home or at a registered clinic. Learn more: sunrisePD.com
#Medsky #Neurosky
